Advertisement
U.S. markets closed
Advertisement

Adverum Biotechnologies, Inc. (ADVM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.9001-0.1099 (-10.88%)
At close: 04:00PM EST
0.9333 +0.03 (+3.69%)
After hours: 04:14PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close1.0100
Open1.0200
Bid0.8819 x 4000
Ask0.9333 x 800
Day's Range0.8800 - 1.0400
52 Week Range0.5310 - 2.3400
Volume408,313
Avg. Volume245,814
Market Cap90.934M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-1.2600
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADVM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adverum Biotechnologies, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

    REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and saf

  • GlobeNewswire

    Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

    REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m.

  • GlobeNewswire

    Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

    - Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - - Cash runway projected into 2